A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
Anyue Yin,Dirk Jan A.R. Moes,Johan G.C. van Hasselt,Jesse J. Swen,Henk-Jan Guchelaar +4 more
- Vol. 8, Iss: 10, pp 720-737
TLDR
The opportunities of a model‐based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.Abstract:
Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer evolution has improved the understanding of anticancer treatment resistance. A better characterization of cancer evolution and subsequent use of this knowledge for personalized treatment would increase the chance to overcome cancer treatment resistance. Model-based approaches may help achieve this goal. In this review, we comprehensively summarized mathematical models of tumor dynamics for solid tumors and of drug resistance evolution. Models displayed by ordinary differential equations, algebraic equations, and partial differential equations for characterizing tumor burden dynamics are introduced and discussed. As for tumor resistance evolution, stochastic and deterministic models are introduced and discussed. The results may facilitate a novel model-based analysis on anticancer treatment response and the occurrence of resistance, which incorporates both tumor dynamics and resistance evolution. The opportunities of a model-based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.read more
Citations
More filters
Book ChapterDOI
The Mathematical Model
TL;DR: The death rate per tumor cell due to immunological response is proportional to the total number of antigen-producing (tumor) cells; thus, the total death rate is quadratic.
Journal ArticleDOI
Cancer modeling: From mechanistic to data-driven approaches, and from fundamental insights to clinical applications
TL;DR: A non-exhaustive overview of models according to their intrinsic features of in silico cancer models is provided, using the hallmarks of cancer as a guidance.
Journal ArticleDOI
Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth
Pierluigi Colli,Hector Gomez,Guillermo Lorenzo,Guillermo Lorenzo,Gabriela Marinoschi,Alessandro Reali,Elisabetta Rocca +6 more
TL;DR: The results suggest that only cytotoxic chemotherapy is required to optimize therapeutic performance and it is shown that the optimal control framework can produce superior solutions to combined therapy with docetaxel and bevacizumab.
Journal ArticleDOI
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
TL;DR: This review is to comprehensively summarize the history of TGD, and present case examples of the recent advance ofTGD modeling (mixture model and joint model), as well as the TGD impact on regulatory decisions, thus illustrating challenges and opportunities.
Journal ArticleDOI
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.
Stefania Crucitta,Federico Cucchiara,Ron H.J. Mathijssen,Joaquin Mateo,Agnes Jager,Arjen Joosse,Antonio Passaro,Ilaria Attili,Iacopo Petrini,Ron H.N. van Schaik,Romano Danesi,Marzia Del Re +11 more
TL;DR: In this paper , the authors focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure across different tumour types, including lung, colorectal, prostate, breast cancer and melanoma.
References
More filters
Journal ArticleDOI
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
TL;DR: Pazopanib 800 mg was shown to be an effective treatment for RCC that increased the tumor shrinkage rate by 267 % compared with placebo and reduced the likelihood of developing new lesions.
Journal ArticleDOI
Image based modeling of tumor growth.
TL;DR: The aim of this review is to highlight the imaging role in tumor growth modeling and provide a worthwhile reference for biomedical and mathematical researchers with respect to tumor modeling using the clinical data to develop personalized models of tumor growth and evaluating the effect of different therapies.
Proceedings ArticleDOI
Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case
Vangelis Sakkalis,Alexandros Roniotis,Christina Farmaki,Ioannis Karatzanis,Konstantinos Marias +4 more
TL;DR: The promising results presented encourage the potential clinical applicability of the proposed model in the glioma case and identify crucial points and direction of further model refinement and research.
Journal ArticleDOI
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
TL;DR: Time‐to‐tumor‐growth (TTG) was the best TGI metric to predict OS and TTG, Eastern Cooperative Oncology Group (ECOG) score, albumin level, and Asian ethnicity were significant covariates in the final OS model.
Journal ArticleDOI
Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme.
Vishal Patel,Leith Hathout +1 more
TL;DR: A novel computational model based on magnetic resonance imaging features of each tumor that replicates the observed progression of glioblastoma more accurately relative to prior techniques is developed and may contribute to the development of more reliable prognostic estimates in patients with gliOBlastoma multiforme.